[go: up one dir, main page]

SG10201809506TA - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Info

Publication number
SG10201809506TA
SG10201809506TA SG10201809506TA SG10201809506TA SG10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA
Authority
SG
Singapore
Prior art keywords
ylmethyl
tetrahydro
quinoline
conditions
skin diseases
Prior art date
Application number
SG10201809506TA
Inventor
Mohammed I Dibas
Edward C Hsia
John E Donello
Daniel W Gil
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809506T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201809506TA publication Critical patent/SG10201809506TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical Compositions Comprising 7-(1H-lmidazol-4-Ylmethyl)-5, 6, 7, 8- Tetrahydro-Quinoline For Treating Skin Diseases And Conditions The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H- lmidazol-4-ylmethyl)-5,6,7,8-tetrahydro- quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof. Fig. 1
SG10201809506TA 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions SG10201809506TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
SG10201809506TA true SG10201809506TA (en) 2018-11-29

Family

ID=47178364

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201809506TA SG10201809506TA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201609145PA SG10201609145PA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201609145PA SG10201609145PA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (22)

Country Link
US (4) US20130123303A1 (en)
EP (3) EP3763370A1 (en)
JP (2) JP6359456B2 (en)
KR (1) KR102004563B1 (en)
CN (1) CN104136029A (en)
AR (1) AR088845A1 (en)
AU (2) AU2012335803B2 (en)
BR (1) BR112014011336A2 (en)
CA (1) CA2855005C (en)
CL (1) CL2014001242A1 (en)
DK (1) DK2776034T3 (en)
ES (1) ES2635421T3 (en)
IL (3) IL232483B (en)
MX (1) MX350662B (en)
MY (1) MY182553A (en)
PH (1) PH12014501051A1 (en)
RU (2) RU2667645C1 (en)
SG (3) SG10201809506TA (en)
TW (3) TW202014189A (en)
UA (1) UA109359C2 (en)
WO (1) WO2013070861A1 (en)
ZA (1) ZA201403396B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2014182610A2 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
FR3061434B1 (en) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA
RU2727695C1 (en) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Method of complex treatment of rhinophyma

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940227D1 (en) * 1998-05-08 2009-02-12 Univ Miami Use of sub-antimicrobial tetracyclines for the treatment of ocular rosacea
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050130906A1 (en) * 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104490884A (en) * 2004-05-25 2015-04-08 桑斯罗萨医药发展公司 Compounds, Formulations, And Methods For Treating Or Preventing Rosacea
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (en) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Method for treating patients for rosacea
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US8338421B2 (en) * 2008-08-01 2012-12-25 Alpha Synergy Development, Inc. Compositions and methods for reversing rebound hyperemia
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (en) * 2009-02-16 2010-08-20 Galderma Res & Dev ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DERMATOLOGICAL DISEASES
AU2010313643B2 (en) * 2009-10-26 2015-11-12 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117378A2 (en) * 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
JP5747391B2 (en) * 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント Improved methods and compositions for safe and effective treatment of erythema
CN103140217B (en) * 2010-08-06 2015-08-19 盖尔德马研究及发展公司 Combinations of compounds for the treatment or prevention of skin diseases

Also Published As

Publication number Publication date
AU2012335803A1 (en) 2014-05-29
US20150231128A1 (en) 2015-08-20
PH12014501051A1 (en) 2022-11-02
AU2012335803B2 (en) 2016-05-26
AU2016216627B2 (en) 2017-10-19
US20130123303A1 (en) 2013-05-16
SG11201402246RA (en) 2014-06-27
TW201713338A (en) 2017-04-16
IL232483B (en) 2018-10-31
AU2016216627A1 (en) 2016-09-08
IL261269A (en) 2018-10-31
ES2635421T3 (en) 2017-10-03
CA2855005A1 (en) 2013-05-16
MX2014005640A (en) 2014-09-22
RU2630978C2 (en) 2017-09-15
MX350662B (en) 2017-09-13
JP6526737B2 (en) 2019-06-05
AR088845A1 (en) 2014-07-10
RU2667645C1 (en) 2018-09-21
KR102004563B1 (en) 2019-07-26
US20160051534A1 (en) 2016-02-25
EP3763370A1 (en) 2021-01-13
IL232483A0 (en) 2014-06-30
EP3184110A1 (en) 2017-06-28
TW202014189A (en) 2020-04-16
NZ624771A (en) 2016-11-25
CL2014001242A1 (en) 2014-11-14
IL268757A (en) 2019-10-31
US20170095466A1 (en) 2017-04-06
EP3184110B1 (en) 2020-10-07
CN104136029A (en) 2014-11-05
UA109359C2 (en) 2015-08-10
BR112014011336A2 (en) 2017-05-02
JP2017149767A (en) 2017-08-31
KR20140107237A (en) 2014-09-04
ZA201403396B (en) 2015-07-29
TWI708604B (en) 2020-11-01
WO2013070861A1 (en) 2013-05-16
EP2776034A1 (en) 2014-09-17
TW201328694A (en) 2013-07-16
US9308201B2 (en) 2016-04-12
JP2014533271A (en) 2014-12-11
SG10201609145PA (en) 2016-12-29
RU2014122758A (en) 2015-12-20
CA2855005C (en) 2016-11-22
JP6359456B2 (en) 2018-07-18
MY182553A (en) 2021-01-25
TWI580424B (en) 2017-05-01
EP2776034B1 (en) 2017-03-22
DK2776034T3 (en) 2017-07-10

Similar Documents

Publication Publication Date Title
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
UA114726C2 (en) 1,4-DISASSEMBLY ANALYSIS OF PIDIDASINE AND METHODS OF TREATMENT OF SMN DEFICIENCES
UA116774C2 (en) Serine/threonine kinase inhibitors
MX2009010407A (en) Fluorinated derivatives of deferiprone.
MX2013012588A (en) Kinase inhibitors.
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MX2011009709A (en) Compounds for treating inflammation and pain.
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
PH12012501389A1 (en) Hedgehog inhibitors
IL268757A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.
IN2013DN02555A (en)
MX2014014066A (en) Chromane compounds.
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
MX2014014814A (en) Pharmaceutical composition for treating inflammation and pain.
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.
MX2014011843A (en) Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma.
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MX2014000870A (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2- ylidene)-1h-benzimidazol-5-amine for treating retinal diseases.